Base de dados : MEDLINE
Pesquisa : D04.210.500.668.651.693.279 [Categoria DeCS]
Referências encontradas : 562 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 57 ir para página                         

  1 / 562 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:24226383
[Au] Autor:Grimes DA; Lopez LM; O'Brien PA; Raymond EG
[Ad] Endereço:Obstetrics and Gynecology, University of North Carolina, School of Medicine, CB#7570, Chapel Hill, North Carolina, USA, 27599-7570.
[Ti] Título:Progestin-only pills for contraception.
[So] Source:Cochrane Database Syst Rev;(11):CD007541, 2013 Nov 13.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The introduction of a new progestin-only oral contraceptive in Europe has renewed interest in this class of oral contraceptives. Unlike the more widely used combined oral contraceptives containing an estrogen plus progestin, these pills contain only a progestin (progestogen) and are taken without interruption. How these pills compare to others in their class or to combined oral contraceptives is not clear. OBJECTIVES: This review examined randomized controlled trials of progestin-only pills for differences in efficacy, acceptability, and continuation rates. SEARCH METHODS: Through October 2013, we searched the computerized databases MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), POPLINE, and LILACS for studies of progestin-only pills. We also searched for current trials via ClinicalTrials.gov and ICTRP. Previous searches also included EMBASE. SELECTION CRITERIA: We included all randomized controlled trials in any language that included progestin-only pills for contraception.  We incorporated any comparison with a progestin-only pill; this could include different doses, other progestin-only pills, combined oral contraceptives, or other contraceptives. DATA COLLECTION AND ANALYSIS: The first author abstracted the data and entered the information into RevMan 5. Another author performed a second, independent data abstraction to verify the initial data entry.We attempted to extract life-table rates (actuarial or continuous) and used the rate difference as the effect measure. Where life-table rates were not published, we used the incidence rate ratio (ratio of Pearl rates). Where only the crude number of events was published, we calculated the Peto odds ratio with 95% confidence interval (CI) using a fixed-effect model. For continuous variables, the mean difference (MD) was computed with 95% CI. Because of disparate exposures, we were not able to combine studies in meta-analysis. MAIN RESULTS: Six trials met the inclusion criteria. We have not found any new studies since the initial review. In the trial comparing the desogestrel versus levonorgestrel progestin-only pill, desogestrel was not associated with a significantly lower risk of accidental pregnancy; the rate ratio was 0.27 (95% CI 0.06 to 1.19). However, the desogestrel progestin-only pill caused more bleeding problems, although this difference was not statistically significant. The trial comparing low-dose mifepristone versus a levonorgestrel progestin-only pill found similar pregnancy rates. In the trial comparing ethynodiol diacetate versus a combined oral contraceptive, irregular cycles occurred in all women assigned to the progestin-only pill (odds ratio 135.96; 95% CI 7.61 to 2421.02). In a trial comparing two progestin-only and two combined oral contraceptives, the progestin-only pill containing levonorgestrel 30 µg had higher efficacy than did the pill containing norethisterone 350 µg. An early trial found megestrol acetate inferior to other progestin-only pills in terms of efficacy. A study of the timing of pill initiation after birth found no important differences, but high losses to follow up undermined the trial. AUTHORS' CONCLUSIONS: Evidence is insufficient to compare progestin-only pills to each other or to combined oral contraceptives.
[Mh] Termos MeSH primário: Anticoncepcionais Orais Hormonais/administração & dosagem
Progestinas/administração & dosagem
[Mh] Termos MeSH secundário: Anticoncepcionais Orais Combinados/administração & dosagem
Anticoncepcionais Orais Hormonais/efeitos adversos
Desogestrel/administração & dosagem
Desogestrel/efeitos adversos
Diacetato de Etinodiol/administração & dosagem
Feminino
Seres Humanos
Levanogestrel/administração & dosagem
Progestinas/efeitos adversos
Ensaios Clínicos Controlados Aleatórios como Assunto
Hemorragia Uterina/induzido quimicamente
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.; REVIEW
[Nm] Nome de substância:
0 (Contraceptives, Oral, Combined); 0 (Contraceptives, Oral, Hormonal); 0 (Progestins); 5W7SIA7YZW (Levonorgestrel); 62H10A1236 (Ethynodiol Diacetate); 81K9V7M3A3 (Desogestrel)
[Em] Mês de entrada:1405
[Cu] Atualização por classe:160602
[Lr] Data última revisão:
160602
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131115
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD007541.pub3


  2 / 562 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21600824
[Au] Autor:Sherk VD; Malone SP; Bemben MG; Knehans AW; Palmer IJ; Bemben DA
[Ad] Endereço:Department of Health and Exercise Science, University of Oklahoma, Norman, OK, USA.
[Ti] Título:Leptin, fat mass, and bone mineral density in healthy pre- and postmenopausal women.
[So] Source:J Clin Densitom;14(3):321-5, 2011 Jul-Sep.
[Is] ISSN:1094-6950
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The purpose was to examine relationships between age, fat mass, and bone mineral density (BMD) with resting leptin levels in premenopausal and postmenopausal women. Young (aged 18-30 yr, n=30) and estrogen-deficient postmenopausal (aged 55-75 yr, n=43) women were recruited. Total body and segmental fat mass and bone-free lean body mass (BFLBM) and total body, lumbar spine, and proximal femur BMD were assessed using dual-energy X-ray absorptiometry. Serum-resting, fasted leptin levels were measured by Immunoradiometric Assay (IRMA), and leptin-to-fat mass ratios were calculated. Young and older women had similar amounts of BFLBM, but older women had greater (p<0.05) amounts of fat mass and 35% higher leptin levels. Age differences in leptin concentrations were no longer significant after controlling for fat mass. Older women had significantly (p<0.05) lower hip BMD values. Age was negatively related (r=-0.29, p<0.05) to leptin:trunk fat ratio. Increases in fat mass, not menopause per se, contributes to higher leptin levels in older women. Relationships between leptin and BMD may be age dependent.
[Mh] Termos MeSH primário: Absorciometria de Fóton
Distribuição da Gordura Corporal
Densidade Óssea
Leptina/sangue
Pós-Menopausa/fisiologia
Pré-Menopausa/fisiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Composição Corporal
Diacetato de Etinodiol
Feminino
Articulação do Quadril/diagnóstico por imagem
Seres Humanos
Vértebras Lombares/diagnóstico por imagem
Meia-Idade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Leptin); 62H10A1236 (Ethynodiol Diacetate)
[Em] Mês de entrada:1110
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110524
[St] Status:MEDLINE
[do] DOI:10.1016/j.jocd.2011.03.010


  3 / 562 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20659389
[Au] Autor:Melvin L
[Ti] Título:Contraceptive failure and the progestogen-only pill.
[So] Source:J Fam Plann Reprod Health Care;36(3):182, 2010 Jul.
[Is] ISSN:1471-1893
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticoncepcionais Orais Sintéticos
Diacetato de Etinodiol
Obesidade
Progestinas
[Mh] Termos MeSH secundário: Adulto
Índice de Massa Corporal
Peso Corporal
Feminino
Seres Humanos
Adesão à Medicação
Falha de Tratamento
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Contraceptives, Oral, Synthetic); 0 (Progestins); 62H10A1236 (Ethynodiol Diacetate)
[Em] Mês de entrada:1010
[Cu] Atualização por classe:161020
[Lr] Data última revisão:
161020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100728
[St] Status:MEDLINE
[do] DOI:10.1783/147118910791749362


  4 / 562 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20659371
[Au] Autor:Chandler J; Nash K
[Ad] Endereço:Central Family Planning Clinic, Grove Road, Norwich NR1 3RH, UK. julia.chandler@nnuh.nhs.uk
[Ti] Título:Contraceptive failure and the progestogen-only pill: the issue of body weight.
[So] Source:J Fam Plann Reprod Health Care;36(3):167-8, 2010 Jul.
[Is] ISSN:1471-1893
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticoncepcionais Orais Sintéticos
Diacetato de Etinodiol
Obesidade
Gravidez não Desejada
Progestinas
[Mh] Termos MeSH secundário: Aborto Induzido
Adulto
Índice de Massa Corporal
Peso Corporal/fisiologia
Feminino
Seres Humanos
Adesão à Medicação
Gravidez
Falha de Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptives, Oral, Synthetic); 0 (Progestins); 62H10A1236 (Ethynodiol Diacetate)
[Em] Mês de entrada:1010
[Cu] Atualização por classe:161020
[Lr] Data última revisão:
161020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100728
[St] Status:MEDLINE
[do] DOI:10.1783/147118910791749191


  5 / 562 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:20091638
[Au] Autor:Grimes DA; Lopez LM; O'Brien PA; Raymond EG
[Ad] Endereço:Behavioral and Biomedical Research, Family Health International, PO Box 13950, Research Triangle Park, North Carolina, USA, NC 27709.
[Ti] Título:Progestin-only pills for contraception.
[So] Source:Cochrane Database Syst Rev;(1):CD007541, 2010 Jan 20.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The introduction of a new progestin-only oral contraceptive in Europe has renewed interest in this class of oral contraceptives. Unlike the more widely used combined oral contraceptives containing an estrogen plus progestin, these pills contain only a progestin (progestogen) and are taken without interruption. How these pills compare to others in their class or to combined oral contraceptives is not clear. OBJECTIVES: This review examined randomized controlled trials of progestin-only pills for differences in efficacy, acceptability, and continuation rates. SEARCH STRATEGY: We searched the computerized databases MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), POPLINE, LILACS, and EMBASE for studies of progestin-only pills. We also searched for current trials via ClinicalTrials.gov and ICTRP. SELECTION CRITERIA: We included all randomized controlled trials in any language that included progestin-only pills for contraception. We incorporated any comparison with a progestin-only pill; this could include different doses, other progestin-only pills, combined oral contraceptives, or other contraceptives. DATA COLLECTION AND ANALYSIS: The first author abstracted the data and entered the information into RevMan 5. Another author performed a second, independent data abstraction to verify the initial data entry. Because of disparate exposures, we were not able to combine studies in meta-analysis. MAIN RESULTS: Six trials met the inclusion criteria. In the trial comparing the desogestrel versus levonorgestrel progestin-only pill, desogestrel was not associated with a significantly lower risk of accidental pregnancy; the rate ratio was 0.27 (95% CI 0.06 to 1.19). However, the desogestrel progestin-only pill caused more bleeding problems, although this difference was not statistically significant. The trial comparing low-dose mifepristone versus a levonorgestrel progestin-only pill found similar pregnancy rates. In the trial comparing ethynodiol diacetate versus a combined oral contraceptive, irregular cycles occurred in all women assigned to the progestin-only pill (odds ratio 135.96; 95% CI 7.61 to 2421.02). In a trial comparing two progestin-only and two combined oral contraceptives, the progestin-only pill containing levonorgestrel 30 mug had higher efficacy than did the pill containing norethisterone 350 mug. An early trial found megestrol acetate inferior to other progestin-only pills in terms of efficacy. A study of the timing of pill initiation after birth found no important differences, but high losses to follow up undermined the trial. AUTHORS' CONCLUSIONS: Evidence is insufficient to compare progestin-only pills to each other or to combined oral contraceptives.
[Mh] Termos MeSH primário: Anticoncepcionais Orais Hormonais/administração & dosagem
Progestinas/administração & dosagem
[Mh] Termos MeSH secundário: Anticoncepcionais Orais Combinados/administração & dosagem
Anticoncepcionais Orais Hormonais/efeitos adversos
Desogestrel/administração & dosagem
Desogestrel/efeitos adversos
Diacetato de Etinodiol/administração & dosagem
Feminino
Seres Humanos
Levanogestrel/administração & dosagem
Progestinas/efeitos adversos
Ensaios Clínicos Controlados Aleatórios como Assunto
Hemorragia Uterina/induzido quimicamente
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Contraceptives, Oral, Combined); 0 (Contraceptives, Oral, Hormonal); 0 (Progestins); 5W7SIA7YZW (Levonorgestrel); 62H10A1236 (Ethynodiol Diacetate); 81K9V7M3A3 (Desogestrel)
[Em] Mês de entrada:1004
[Cu] Atualização por classe:140521
[Lr] Data última revisão:
140521
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100122
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD007541.pub2


  6 / 562 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19836081
[Au] Autor:Coromina Sadurni M; Rodie JU; de Montagut LM; Sánchez Autet M
[Ad] Endereço:Sant Joan de Déu-Serveis de Salut Mental, Fundació Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain. martacoromina@yahoo.com
[Ti] Título:The use of oral contraceptives as a prevention of recurrent premenstrual psychosis.
[So] Source:Psychiatry Res;170(2-3):290-1, 2009 Dec 30.
[Is] ISSN:0165-1781
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Premenstrual psychosis is a rare and not formally recognized disorder (DSM-IVR, ICD-10). The literature mainly consists of clinical cases. There have been preliminary reports of improvement in such cases after administration of oral contraceptives. We present a case of premenstrual psychosis in which hormonal treatment was effective in preventing symptomatic relapses.
[Mh] Termos MeSH primário: Acetato de Clormadinona/uso terapêutico
Anticoncepcionais Orais Sintéticos/uso terapêutico
Diacetato de Etinodiol/análogos & derivados
Transtornos Psicóticos/tratamento farmacológico
Transtornos Psicóticos/prevenção & controle
[Mh] Termos MeSH secundário: Adulto
Diacetato de Etinodiol/uso terapêutico
Feminino
Seres Humanos
Escalas de Graduação Psiquiátrica
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptives, Oral, Synthetic); 0SY050L61N (Chlormadinone Acetate); 62H10A1236 (Ethynodiol Diacetate); 9E01C36A9S (ethynodiol)
[Em] Mês de entrada:1001
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:091020
[St] Status:MEDLINE
[do] DOI:10.1016/j.psychres.2009.02.015


  7 / 562 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18358396
[Au] Autor:Hernandez-Vaquero D; Fernandez-Carreira JM; Garcia-Sandoval MA
[Ti] Título:"A randomized clinical trial of cementless femoral stems with and without hydroxyapatite/tricalcium-phosphate coating: an 8- to 12-year follow-up study" by Yoon et al.
[So] Source:J Arthroplasty;23(3):486-7; author reply 487, 2008 Apr.
[Is] ISSN:0883-5403
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Artroplastia de Quadril
Materiais Revestidos Biocompatíveis
Prótese de Quadril
Hidroxiapatitas
[Mh] Termos MeSH secundário: Diacetato de Etinodiol
Seres Humanos
Osseointegração
Desenho de Prótese
Falha de Prótese
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Coated Materials, Biocompatible); 0 (Hydroxyapatites); 124097-42-3 (hydroxyapatite-tricalciumphosphate composite); 62H10A1236 (Ethynodiol Diacetate)
[Em] Mês de entrada:0806
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080325
[St] Status:MEDLINE
[do] DOI:10.1016/j.arth.2007.11.009


  8 / 562 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:17915765
[Au] Autor:Siddique YH; Ara G; Beg T; Afzal M
[Ad] Endereço:Department of Zoology, Section of Genetics, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202 002, India. yasir_hasansiddique@rediffmail.com
[Ti] Título:Protective role of nordihydroguaiaretic acid (NDGA) against the genotoxic damage induced by ethynodiol diacetate in human lymphocytes in vitro.
[So] Source:J Environ Biol;28(2):279-82, 2007 Apr.
[Is] ISSN:0254-8704
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:Antioxidants and plant products are reported to reduce the genotoxic damage of steroids. In our present study we have tested different dosages of nordihydroguaiaretic acid (NDGA) against the genotoxic damage induced by ethynodiol diacetate in the presence of S9 mix. Treatments with nordihydroguaiaretic acid (NDGA) results in the reduction of the genotoxic damage. A significant decrease was observed at all the tested doses of NDGA in sister chromatic exchanges of number of abnormal cells. The results suggest a protective role of NDGA against the genotoxic damage.
[Mh] Termos MeSH primário: Dano ao DNA/efeitos dos fármacos
Diacetato de Etinodiol/toxicidade
Linfócitos/efeitos dos fármacos
Masoprocol/farmacologia
Mutagênicos/toxicidade
Substâncias Protetoras/farmacologia
[Mh] Termos MeSH secundário: Células Cultivadas
Aberrações Cromossômicas/efeitos dos fármacos
Anticoncepcionais Orais Sintéticos/toxicidade
Feminino
Seres Humanos
Linfócitos/metabolismo
Troca de Cromátide Irmã/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Contraceptives, Oral, Synthetic); 0 (Mutagens); 0 (Protective Agents); 62H10A1236 (Ethynodiol Diacetate); 7BO8G1BYQU (Masoprocol)
[Em] Mês de entrada:0801
[Cu] Atualização por classe:170203
[Lr] Data última revisão:
170203
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:071006
[St] Status:MEDLINE


  9 / 562 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:17763168
[Au] Autor:Keeling AN; O'Dwyer H; Lyon S; O'Kelly P; McGrath FP; Conlon PJ; Lee MJ
[Ad] Endereço:Department of Academic Radiology, Beaumont Hospital, Beaumont Road, Dublin, Ireland.
[Ti] Título:Do AshSplit haemodialysis catheters provide better flow rates in the long term?
[So] Source:Ren Fail;29(6):721-9, 2007.
[Is] ISSN:0886-022X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Recently, interventional radiologists have adopted an increasingly prominent role in the placement and management of hemodialysis catheters, as well as in the research and development of new and better catheters. The purpose of this study was to evaluate the viability and hemodialysis efficiency of the AshSplit catheter and the Permcath catheter. METHODS: 204 consecutive patients requiring radiological insertion of hemodialysis catheters were followed, retrospectively, over a 42-month period. Both hemodialysis catheters were placed using a combination of ultrasonic and fluoroscopic guidance and tunneled appropriately. Information collected included catheter insertion sites, insertion complications, catheter duration, and final outcome. RESULTS: Over the study period of two years, 269 catheters were placed into 204 patients with end stage renal failure. Patients received either an AshSplit (101 patients, 127 catheters) or a Permcath (103 patients, 142 catheters). Vascular access route of choice was the right internal jugular vein (67% AshSplit, 71% Permcath). Insertion complications occurred in 18 patients overall (6.6%), with only 1 requiring further intervention (hemopneumothorax). Flow rates averaged 259 mls/min for AshSplits and 248 mls/min for Permcaths (p < 0.001). Follow-up of catheter viability for 42 months yielded a mean AshSplit catheter duration of 246 days (range 6-932) and 239 days (range 1-1,278) for Permcath (p = 0.46). Reasons for catheter failure and elective catheter removal were similar in both groups; however, Permcaths required significantly more thrombolysis than AshSplits, p < 0.001. CONCLUSION: The AshSplit provides significantly better flow rates and less thrombolysis compared to the Permcath, with similar catheter dwell times.
[Mh] Termos MeSH primário: Cateteres de Demora
Diálise Renal
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Cateterismo Venoso Central/instrumentação
Remoção de Dispositivo
Diacetato de Etinodiol
Feminino
Seres Humanos
Veias Jugulares
Falência Renal Crônica/terapia
Masculino
Meia-Idade
Radiografia Intervencionista
Análise de Sobrevida
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
62H10A1236 (Ethynodiol Diacetate)
[Em] Mês de entrada:0711
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:070901
[St] Status:MEDLINE


  10 / 562 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:15946343
[Au] Autor:Herzog AG; Farina EL; Blum AS
[Ad] Endereço:Harvard Neuroendocrine Unit, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. aherzog@bidmc.harvard.edu
[Ti] Título:Serum valproate levels with oral contraceptive use.
[So] Source:Epilepsia;46(6):970-1, 2005 Jun.
[Is] ISSN:0013-9580
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticonvulsivantes/sangue
Anticoncepcionais Orais Combinados/efeitos adversos
Epilepsia/sangue
Epilepsia/tratamento farmacológico
Etinilestradiol/efeitos adversos
Diacetato de Etinodiol/efeitos adversos
Ácido Valproico/sangue
[Mh] Termos MeSH secundário: Adulto
Anticonvulsivantes/farmacocinética
Anticonvulsivantes/uso terapêutico
Comorbidade
Anticoncepcionais Orais Combinados/farmacocinética
Anticoncepcionais Orais Combinados/uso terapêutico
Interações Medicamentosas
Epilepsia/epidemiologia
Etinilestradiol/farmacocinética
Etinilestradiol/uso terapêutico
Diacetato de Etinodiol/farmacocinética
Diacetato de Etinodiol/uso terapêutico
Feminino
Seres Humanos
Menorragia/tratamento farmacológico
Menorragia/epidemiologia
Distúrbios Menstruais/tratamento farmacológico
Distúrbios Menstruais/epidemiologia
Ácido Valproico/farmacocinética
Ácido Valproico/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticonvulsants); 0 (Contraceptives, Oral, Combined); 423D2T571U (Ethinyl Estradiol); 614OI1Z5WI (Valproic Acid); 62H10A1236 (Ethynodiol Diacetate); 8075-78-3 (SC-11800 EE)
[Em] Mês de entrada:0506
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:050611
[St] Status:MEDLINE



página 1 de 57 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde